421 patents
Page 6 of 22
Utility
Methods of treating autoimmune disease using a domain antibody directed against CD40L
11 Oct 22
Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided.
Marek Honczarenko, Vaishali Shah, Lixin Lang, Urvi Aras, Diane Shevell, Christine Kratt, Karen Price, Suzanne Suchard
Filed: 20 Feb 20
Utility
Antibodies against OX-40 and uses thereof
11 Oct 22
Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40.
Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
Filed: 13 Apr 20
Utility
Methods for culturing cells and kits and apparatus for same
11 Oct 22
Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes.
Lothar Germeroth, Christian Stemberger, Patricia Gräf, Keenan Bashour
Filed: 20 Oct 16
Utility
Substituted indole compounds useful as inhibitors of TLR7/8/9
20 Sep 22
Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Brian K. Whiteley, John L. Gilmore
Filed: 3 Aug 18
Utility
Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
20 Sep 22
Peter Tai Wah Cheng, Yan Shi, Robert F. Kaltenbach, III, Ying Wang, Hao Zhang
Filed: 18 Dec 18
Utility
Spiroheptanyl hydantoins as rock inhibitors
20 Sep 22
Benjamin P. Vokits, Scott A. Shaw
Filed: 11 Jul 18
Utility
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
20 Sep 22
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein.
Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
Filed: 11 Jan 19
Utility
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
20 Sep 22
James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
Filed: 3 Jan 19
Utility
Fibronectin based scaffold proteins
20 Sep 22
Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided.
Dasa Lipovsek, Jonathan H. Davis
Filed: 10 Jan 20
Utility
Aminoimidazopyridazines as kinase inhibitors
13 Sep 22
Michael E. Mertzman, Carolyn Diane Dzierba, Jason M. Guernon, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Steven H. Spergel
Filed: 29 Oct 18
Utility
Fast-off rate serum albumin binding fibronectin type III domains
6 Sep 22
Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin.
Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
Filed: 21 Jan 20
Utility
6-azaindole compounds
30 Aug 22
Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
Filed: 18 Dec 18
Utility
Cyclic dinucleotides as anticancer agents
30 Aug 22
Brian E. Fink, Yufen Zhao, Libing Chen, Audris Huang
Filed: 16 Oct 18
Utility
Amide substituted indole compounds useful as TLR inhibitors
23 Aug 22
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Tasir Shamsul Haque, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Rushith Kumar Anumula
Filed: 18 Dec 18
Utility
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
23 Aug 22
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
Filed: 12 Sep 18
Utility
Method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids
23 Aug 22
The present invention relates generally to a method of monitoring pharmacodynamic responses mediated by in vivo administration of glucocorticoids.
Julie Carman, Yanhua Hu
Filed: 28 Aug 18
Utility
Aryl and heteroaryl substituted indole compounds
23 Aug 22
Alaric J. Dyckman, Christopher P. Mussari, Tasir Shamsul Haque, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy, Rushith Kumar Anumula
Filed: 19 Dec 18
Utility
Compounds useful as immunomodulators
16 Aug 22
The present disclosure generally relates to compounds useful as immunomodulators.
Kap-Sun Yeung, Juliang Zhu, Paul Michael Scola
Filed: 23 Jan 19
Utility
Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
16 Aug 22
The invention provides methods and compositions for identifying binding polypeptides (e.g., antibodies or antigen binding fragments thereof) that specifically binds to a cell-surface antigen.
Yan Chen, Steven M. Shamah
Filed: 21 Jun 19
Utility
Fibronectin binding domains with reduced immunogenicity
9 Aug 22
Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided.
Jonathan Davis, Dasa Lipovsek, Ray Camphausen
Filed: 9 Mar 20